Status:
RECRUITING
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The researchers are doing this study to look at changes in Ki67 expression after at least 2 weeks of endocrine therapy in people with ER+/HER2- breast cancer undergoing cancer removal surgery. Partici...
Eligibility Criteria
Inclusion
- Postmenopausal women aged ≥18 years with biopsy-proven stage I-III invasive breast cancer that is ER+/HER2-
- Scheduled to undergo upfront surgery
- Eligible for genetic testing in accordance with National Comprehensive Cancer Network guidelines(BRCA2 arm only)
Exclusion
- History of breast cancer
- Receipt of ET for risk reduction in the previous 3 months
- Stage IV disease at presentation
- Scheduled to undergo neoadjuvant systemic chemotherapy
- Pregnant
Key Trial Info
Start Date :
November 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2028
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT06127979
Start Date
November 6 2023
End Date
November 1 2028
Last Update
September 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States, 10065